Clinical Trial Update: GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GLP-1 receptor agonists to reduce alcohol use and cardiovascular risk in people with HIV. The study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder
• Cardiovascular Disease
• HIV Infection
• Tobacco Use Disorder

Drugs mentioned

• GLP-1 receptor agonists

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: HIV, Alcohol | Phase 2 | Status: NOT_YET_RECRUITING